Requires physician to offer to test patient for dihydropyrimidine dehydrogenase deficiency prior to patient undergoing chemotherapy.
Impact
If enacted, A2645 would require coverage for this specific test under health insurance policies delivered, issued, or renewed in New Jersey. Insurers would be required to cover expenses associated with one annual test for dihydropyrimidine dehydrogenase deficiency, making it a mandated benefit under both individual and group health insurance plans. This would ensure that patients have access to necessary testing, potentially reducing the risks associated with chemotherapy treatments across the state.
Summary
Assembly Bill A2645 aims to enhance patient safety in chemotherapy treatment by mandating that physicians offer testing for dihydropyrimidine dehydrogenase deficiency before initiating chemotherapy. This genetic condition can impede the body's ability to metabolize certain chemotherapy drugs, potentially leading to severe adverse reactions in patients. The introduction of such a testing protocol aims to identify individuals at risk and manage their treatment plans accordingly to reduce harmful side effects, thus promoting safer chemotherapy practices.
Contention
While the bill is primarily focused on enhancing patient safety, it may face scrutiny regarding its implications for health insurance costs. Some stakeholders may argue that requiring insurance companies to cover this testing could lead to increased premiums for policyholders as insurers balance the costs of these mandated benefits. Conversely, proponents might argue that the long-term savings from preventing severe chemotherapy reactions could outweigh initial costs. As discussions progress, it will be essential to address these concerns and ensure comprehensive stakeholder engagement.
Health: diseases; dissemination of information about cytomegalovirus (CMV) to certain individuals and in certain situations; provide for. Amends secs. 5431 & 5432 of 1978 PA 368 (MCL 333.5431 & 333.5432) & adds sec. 5143.